# WVE earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/WVE) · [Earnings tab](https://www.lopjlb.com/stock/WVE?tab=earnings)

Updated: 2026-07-30T12:10:12

Quarters analyzed: 8

## Cross-quarter narrative

Across seven quarters, Wave Life Sciences progressed from a single positive Huntington's disease (HD) readout to a diversified RNA‑medicine pipeline with four clinical programs. In mid‑2024, SELECT‑HD success for WVE‑003 and a Takeda opt‑in were accompanied by expectations for DMD dystrophin data, AATD proof‑of‑mechanism, and an INHBE CTA filing, with cash projected into Q4 2025. By late 2024 the company reported three positive datasets, FDA support for an HD accelerated‑approval pathway, and outlined four 2025 milestones spanning obesity, DMD, AATD, and HD. Cash runway extended to 2027 in early 2025 as WVE‑007 (obesity siRNA) enrolled its first cohort, WVE‑006 (AATD RNA editing) showed proof‑of‑mechanism, and DMD 48‑week data supported a 2026 NDA. Through mid‑2025 momentum remained strong across all modalities. The November 2025 call introduced the first explicit fears: obesity efficacy benchmarks versus incretins, safety at higher doses, US enrollment timing, regulatory uncertainty, and commercial adoption of a non‑incretin approach. By February 2026, cash reached $602 M (runway to Q3 2028) bolstered by a GSK collaboration, while milestones for WVE‑007 (multiple dose cohorts), WVE‑006 (multi‑dose and regulatory feedback), and a Phase IIa INLIGHT trial were all on track. New fears emerged around regulatory acceptance of accelerated approval for WVE‑006, translation of low‑BMI obesity data, competition in activin E/ALK7, payer demand for weight‑loss outcomes, and long‑term safety of chronic INHBE silencing. The 2026 Q1 call provided no new data.

## Latest CallCard · Q1

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** —
- **2025 Q4:** Wave Life Sciences highlighted progress on obesity candidate WVE-007 and RNA editing programs, reaffirmed data timelines and cash runway, while fielding analyst questions on regulatory paths and trial execution.
- **2025 Q3:** Wave Life Sciences reported encouraging early obesity data for WVE-007, strong AATD results for WVE-006, and outlined multiple pipeline milestones while noting upcoming data reads in 2026.
- **2025 Q2:** Wave Life Sciences reports strong momentum across RNA editing (AATD), siRNA (obesity), exon skipping (DMD), and allele-selective HD programs, with multiple clinical data readouts expected in H2 2025 and cash runway into 2027.','tone':{'mgmt':0.7,'mgmt_rationale':'Prepared remarks emphasize "strong m
- **2025 Q1:** Wave advances RNA pipeline: INHBE obesity 2 cohorts dosed (data H2'25), AATD RNA editing multi-dosing (data Q3/fall'25), DMD N531 48-wk data supports '26 NDA, HD WVE-003 IND H2'25; cash into '27.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Prepared remarks emphasize "tremendous progress", "breakthroug
- **2024 Q4:** Wave Life Sciences advances four clinical programs: WVE-007 obesity siRNA enrolled first cohort, data H2'25; WVE-006 AATD RNA editing shows proof of mechanism, multi-dosing underway; WVE-N531 DMD 48-week data due March'25; WVE-003 HD Phase 2/3 planning with caudate endpoint, IND H2'25; cash runway i
- **2024 Q3:** Wave Life Sciences reports three positive clinical datasets, FDA support for HD accelerated approval pathway, and advances four programs toward 2025 milestones including obesity CTA filing, DMD 48-week data, AATD multi-dose data, and HD IND submission.','tone': {'mgmt': 0.85, 'mgmt_rationale': 'Prep
- **2024 Q2:** Wave reports SELECT-HD success for WVE-003 (HD), submits Takeda opt-in; expects N531 dystrophin data Q3, RestorAATion-2 proof-of-mechanism Q4, and INHBE CTA filing by year-end; cash runway to Q4'25.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights positive SELECT-HD data, multiple upc

## Theme arcs

- **Clinical pipeline breadth** (improving): Expanded from HD‑focused to four concurrent programs (obesity, AATD, DMD, HD) with multiple readouts.
- **Cash runway** (improving): Extended from Q4 2025 to Q3 2028 ($602 M) with GSK milestone upside.
- **Regulatory pathway clarity** (stable): FDA support for HD accelerated approval noted early; later uncertainty around WVE‑006 accelerated approval and WVE‑007 weight‑loss endpoints.
- **Obesity program (WVE‑007)** (improving): Advanced from CTA filing to multiple dose cohorts with early data; Phase IIa INLIGHT trial initiated.
- **AATD RNA editing (WVE‑006)** (improving): Progressed from proof‑of‑mechanism to multi‑dose cohorts and regulatory feedback for accelerated approval.
- **DMD exon skipping (WVE‑N531)** (stable): 48‑week data supports 2026 NDA; timeline consistent across calls.
- **HD allele‑selective (WVE‑003)** (stable): IND submission planned H2 2025; Phase 2/3 planning with caudate endpoint.
- **Safety and efficacy concerns** (new): First articulated in Q3 2025: obesity benchmark vs semaglutide, higher‑dose safety, long‑term INHBE silencing.
- **Competitive landscape** (new): Activin E/ALK7 competition noted in Q4 2025.
- **Reimbursement and commercial adoption** (new): Payer demand for weight‑loss outcomes and non‑incretin acceptance raised in Q4 2025.

## Guidance path

2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/WVE`